04X Stock Chart & Stats
€5.50
-€0.41(-6.77%)
At close: 4:00 PM EST
€5.50
-€0.41(-6.77%)
Day’s Range― - ―
52-Week Range€3.66 - €14.34
Previous CloseN/A
Volume0.00
Average Volume (3M)226.00
Market Cap
€1.23B
Enterprise Value€469.27
Total Cash (Recent Filing)€233.22M
Total Debt (Recent Filing)€38.78M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 11, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding104,721,100
10 Day Avg. Volume385
30 Day Avg. Volume226
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.09Price Target Upside119.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.9
Revenue Forecast (FY)€69.21M
Bulls Say, Bears Say
Bulls Say
Medicare Coverage Expansion For NeXT PersonalExpanded Medicare coverage for NeXT Personal materially increases the addressable reimbursed patient population, lowering adoption friction and enabling higher ASPs. Durable reimbursement broadens clinical use, supports sustained volume growth and underpins margin recovery as reimbursed testing scales.
Rapid Clinical Volume Growth And Physician RetentionRapid, sustained test volume increases and extremely high physician retention indicate durable clinical adoption and sticky demand. Scaling clinical throughput supports recurring revenue, payor engagement, and learning-curve cost improvements, making future margin expansion more achievable over months.
Strong Liquidity And Modest LeverageA large cash balance combined with low debt provides runway to fund commercial investments and MRD scaling without immediate refinancing. This financial flexibility lets management pursue reimbursement and product rollout timelines, reducing short-term solvency risk while they execute growth plans.
Bears Say
Shrinking Revenue And Top-line WeaknessTop-line contraction and intentional migration away from legacy revenue leave near-term revenue growth fragile. Until reimbursed clinical and MRD commercial volumes consistently offset legacy declines, the company faces pressured revenue trends that can stress operating plans and cash runway.
Severe Margin Compression And Persistent LossesSharp gross margin deterioration and large operating losses reflect unreimbursed test dilution and mix shifts. Sustained low margins undermine the path to profitability; margin recovery hinges on payer adoption and higher-margin mix, risks that can delay sustainable earnings for many quarters.
High Cash Burn And Dependence On Payer DecisionsSignificant ongoing cash burn and explicit multi‑quarter cash usage guidance create financing sensitivity. Because margin improvement depends on MolDX/payer decisions, delayed coverage could force additional capital raises or scaled-back investments, impairing strategic execution and diluting shareholder value over time.
Personalis News
04X FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was €3.66 and its highest was €14.34 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is €1.23B.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Aug 11, 2026 which is in 20 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on May 07, 2026. The company reported -€0.254 earnings per share for the quarter, missing the consensus estimate of -€0.238 by -€0.017.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.23.
How many shares outstanding does Personalis have?
Personalis has 104,721,100 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -€0.254 in its last earnings report, missing expectations of -€0.238. Following the earnings report the stock price went down -2.759%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in DE:04X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.09 (119.85% Upside)
€12.09 (119.85% Upside)
Blogger Sentiment
Bullish
DE:04X Sentiment 70%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.06%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
04X Stock 12 Month Forecast
Average Price Target
€12.09
▲(119.85% Upside)
Technical Analysis
Standard BioTools
―
Myriad Genetics
―
CareDx
―
Fulgent Genetics
―
Castle Biosciences
―